Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Biot Korea Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner within 1 distinct art unit. This represents a singular and focused prosecution effort for the company's current portfolio. Practitioners should recognize that this case represents the company's current engagement with the patent office in this technology area. The focus on a single examiner and unit suggests a streamlined interaction with the office.
MARVICH, MARIA is the busiest examiner, holding the busiest examiner pending count of 1. Since there is only 1 distinct examiner and 1 distinct art unit, the company's current prosecution success is dependent on this one case. Practitioners should focus on the specific tendencies of the 1 examiner, as they are the only individual currently reviewing the company's pending office actions. The outcome of the 1 pending office action will define the company's current success rate within the 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARVICH, MARIA | 1 | 55.0% | +28.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18965372 | METHOD FOR PRODUCING HYDROGEL MICROBEADS CAPABLE OF MAGNETIC ACTUATION FOR DELIVERY OF THERAPEUTIC SUBSTANCE, HYDROGEL MICROBEADS PRODUCED THEREBY, AND PHARMACEUTICAL COMPOSITION FOR TREATING MUSCULOSKELETAL DISORDERS COMPRISING SAME | MARVICH, MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18965372 | METHOD FOR PRODUCING HYDROGEL MICROBEADS CAPABLE OF MAGNETIC ACTUATION FOR DELIVERY OF THERAPEUTIC SUBSTANCE, HYDROGEL MICROBEADS PRODUCED THEREBY, AND PHARMACEUTICAL COMPOSITION FOR TREATING MUSCULOSKELETAL DISORDERS COMPRISING SAME | MARVICH, MARIA | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18965372 | METHOD FOR PRODUCING HYDROGEL MICROBEADS CAPABLE OF MAGNETIC ACTUATION FOR DELIVERY OF THERAPEUTIC SUBSTANCE, HYDROGEL MICROBEADS PRODUCED THEREBY, AND PHARMACEUTICAL COMPOSITION FOR TREATING MUSCULOSKELETAL DISORDERS COMPRISING SAME | MARVICH, MARIA | 1634 | §103§112 | Non-Final OA | — | Pending | Dec 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBiot Korea Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Maria Marvich has the most, with 1 of Biot Korea Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
